Skip to main content
. 2022 Jan 7;17:91–104. doi: 10.2147/IJN.S344491

Figure 3.

Figure 3

In vitro biocompatibility and anti-inflammatory efficacy of MC-PαLA-MP NPs. (AC) Viabilities of (A) astrocytes, (B) BV2 microglial cells, and (C) PC12 cells after incubation with different concentrations of PαLA-MP NPs or MC-PαLA-MP NPs. (DF) Release rates of (D) TNF-α, (E) IL-1β, and (F) IL-6 from lipopolysaccharide-activated BV2 cells treated with the vehicle (phosphate buffer saline), MC-PαLA-MP NPs, or various NP components. ****p < 0.0001; ***p < 0.001; **p < 0.01.

Abbreviation: ns, no significant difference.